Advertisement
Journal Home
Search for
Advanced Search - MEDLINE - My Recent Searches - My Saved Searches - Search Tips
More periodicals:

44 Periodical Search Results

You searched for "fulvestrant" OR "zd9238" OR "zd 9238" OR "faslodex" OR "zm182780" OR "zd182780" OR "zd 182780" OR "zm 182780" OR "ici182780" OR "ici 182780" OR "ici 182 780" within European Journal of Cancer

New Search | Edit Search | Save Search | Save Search as an E-mail Alert

  Viewing 1-20  of 44 results   Next 20>

Results Page:  [1]  2  3

display abstract citation download email a colleague
Display:

  1. Selective oestrogen receptor downregulator
    Anthony A. Howell
    European Journal of Cancer
    September 2002 (Vol. 38Supplement 6, Pages 61-62)
    Full Text | Full-Text PDF (59 KB)

  1. Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
    I Vergote, on behalf of the Faslodex 0020 and 0021 investigators
    European Journal of Cancer
    September 2002 (Vol. 38Supplement 6, Pages 57-58)
    Full Text | Full-Text PDF (68 KB)

  1. Faslodex (ICI 182780) an oestrogen receptor downregulator
    A. Howell
    European Journal of Cancer
    September 2000 (Vol. 36Supplement 4, Pages 87-88)
    Abstract | Full Text | Full-Text PDF (69 KB)

  1. ICI 182,780 (‘FASLODEX’) 250 mg monthly Intramuscular (I.M.) injection shows consistent Pharmacokinetic (PK) profiles when given as either 1 × 5 ml or 2 × 2.5 ml injections in postmenopausal women with Advanced Breast Cancer (ABC)
    J.F.R. Robertson, B. Erikstein, C.K. Osborne, J. Pippen, M. Harrison
    European Journal of Cancer
    September 2001 (Vol. 37Supplement 5, Pages 8-9)
    Full-Text PDF (261 KB)

  1. What clinicians need to know about antioestrogen resistance in breast cancer therapy
    Amalia Milano, Lissandra Dal Lago, Christos Sotiriou, Martine Piccart, Fatima Cardoso
    European Journal of Cancer
    November 2006 (Vol. 42, Issue 16, Pages 2692-2705)
    Abstract | Full Text | Full-Text PDF (385 KB)

  1. Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experience
    G.G. Steger, R. Bartsch, C. Wenzel, U. Pluschnig, D. Hussian, U. Sevelda, G.J. Locker, M.F. Gnant, R. Jakesz, C.C. Zielinski
    European Journal of Cancer
    November 2005 (Vol. 41, Issue 17, Pages 2655-2661)
    Abstract | Full Text | Full-Text PDF (139 KB)

  1. Endocrine treatment options for advanced breast cancer – the role of fulvestrant
    J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, A. Makris, J.W.R. Nortier, K. Possinger, L.-E. Rutqvist
    European Journal of Cancer
    February 2005 (Vol. 41, Issue 3, Pages 346-356)
    Abstract | Full Text | Full-Text PDF (402 KB)

  1. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer
    R.A. McClelland, J.M.W. Gee, A.B. Francis, J.F.R. Robertson, R.W. Blarney, A.E. Wakeling, R.I. Nicholson
    European Journal of Cancer
    March 1996 (Vol. 32, Issue 3, Pages 413-416)
    Abstract | Abstract + References | Full-Text PDF (464 KB)

  1. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer , 17 December 2007
    O.E. Young, L. Renshaw, E.J. Macaskill, S. White, D. Faratian, J.St.J. Thomas, J.M. Dixon
    European Journal of Cancer
    February 2008 (Vol. 44, Issue 3, Pages 391-399)
    Abstract | Full Text | Full-Text PDF (177 KB)

  1. Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
    L. Mauriac, J.E. Pippen, J. Quaresma Albano, S.Z. Gertler, C.K. Osborne
    European Journal of Cancer
    June 2003 (Vol. 39, Issue 9, Pages 1228-1233)
    Abstract | Full Text | Full-Text PDF (196 KB)

  1. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer
    J.F.R. Robertson, V. Semiglazov, G. Nemsadze, G. Dzagnidze, M. Janjalia, R.I. Nicholson, J.M.W. Gee, J. Armstrong, for the Study 41 Investigators
    European Journal of Cancer
    January 2007 (Vol. 43, Issue 1, Pages 64-70)
    Abstract | Full Text | Full-Text PDF (127 KB)

  1. ZD1839 (‘Iressa’) improves the antitumour activity of tamoxifen (‘Nolvadex’) and ICI 182, 780 (‘Faslodex’) in antihormone responsive breast cancer
    European Journal of Cancer
    November 2002 (Vol. 38Supplement 7, Page S59)
    Full-Text PDF (141 KB)

  1. ICI 182,780 (‘FASLODEX’) is at least as effective as anatrozole (Arimidex™) in post-menopausal women with advanced breast cancer progressing on prior endocrine treatment
    A. Howell, J.F.R. Robertson, J.Quaresma Albano, A. Aschermannova, L. Mauriac, U.R. Kleeberg, I. Bergote, B. Erikstein, A. Webster, C. Morris
    European Journal of Cancer
    September 2001 (Vol. 37Supplement 5, Page 9)
    Full-Text PDF (130 KB)

  1. Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world?
    M.J. Piccart-Gebhart, S.M. Loi
    European Journal of Cancer
    February 2005 (Vol. 41, Issue 3, Pages 341-343)
    Full Text | Full-Text PDF (224 KB)

  1. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance
    I Fichtner, M Becker, R Zeisig, A Sommer
    European Journal of Cancer
    April 2004 (Vol. 40, Issue 6, Pages 845-851)
    Abstract | Full Text | Full-Text PDF (376 KB)

  1. The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines
    O. Treeck, K. Diedrich, O. Ortmann
    European Journal of Cancer
    June 2003 (Vol. 39, Issue 9, Pages 1302-1309)
    Abstract | Full Text | Full-Text PDF (471 KB)

  1. The oestrogen receptor and its selective modulators in gynaecological and breast cancer
    I Vergote, P Neven, P van Dam, R Serreyn, F De Prins, Ph De Sutter, G Albertyn
    European Journal of Cancer
    September 2000 (Vol. 36Supplement 4, Pages 1-9)
    Full Text | Full-Text PDF (120 KB)

  1. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro
    M.E Nuttall, P.W Fisher, L.J Suva, M Gowen
    European Journal of Cancer
    September 2000 (Vol. 36Supplement 4, Pages 63-64)
    Abstract | Full Text | Full-Text PDF (149 KB)

  1. Selective oestrogen receptor modulation: molecular pharmacology for the millennium
    A.S. Levenson, V.C. Jordan
    European Journal of Cancer
    November 1999 (Vol. 35, Issue 12, Pages 1628-1639)
    Abstract | Full Text | Full-Text PDF (253 KB)

  1. Selective oestrogen receptor modulation: molecular pharmacology for the millennium
    A.S. Levenson, V.C. Jordan
    European Journal of Cancer
    December 1999 (Vol. 35, Issue 14, Pages 1974-1985)
    Abstract | Full Text | Full-Text PDF (374 KB)
display abstract citation download email a colleague
Display:

  Viewing 1-20  of 44 results   Next 20>

Results Page:  [1]  2  3

New Search | Edit Search | Save Search | Save Search as an E-mail Alert

Advertisement

Copyright © 2009 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us |
The content on this site is intended for health professionals.